Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Viviane Teixeira Loiola de Alencar"'
Autor:
Rafaela Pirolli, Viviane Teixeira Loiola de Alencar, Felipe Leonardo Estati, Adriana Regina Gonçalves Ribeiro, Daniella Yumi Tsuji Honda, Mariana de Oliveira, Joao Paulo da Silveira Nogueira Lima, Elizabeth Santana dos Santos, Andrea Paiva Gadelha Guimarães, Glauco Baiocchi, Alexandre André Balieiro Anastácio da Costa
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
Abstract Background Benefit of carboplatin and dose-dense weekly paclitaxel (ddCT) in first line treatment of ovarian cancer patients has been different in Western and Asian studies. In the present study we compare progression-free survival (PFS) of
Externí odkaz:
https://doaj.org/article/94eed9345bc54a13aa448b9619bd3b3e
Autor:
Marcos Pedro Guedes Camandaroba, Viviane Teixeira Loiola de Alencar, Vladmir Cláudio Cordeiro de Lima, Rafaela Pirolli, Camilla Albina Zanco Fogassa
Publikováno v:
Journal of Thoracic Oncology. 16:1379-1391
Introduction Brain metastases (BMs) occur in 40% of patients with lung cancer. The activity of immunotherapy in these patients, however, remains controversial, as the cornerstone treatment is radiotherapy (RT). Because RT is associated with adverse e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::310858df23e791e16a1faa58376b9c8b
https://doi.org/10.1016/j.jtho.2021.04.014
https://doi.org/10.1016/j.jtho.2021.04.014
Autor:
Adriana Regina Gonçalves Ribeiro, Alexandre Andre Balieiro Anastacio da Costa, Rafaela Pirolli, Viviane Teixeira Loiola de Alencar, Glauco Baiocchi, Felipe Leonardo Estati, Maria Nirvana Formiga, Andrea Paiva Gadelha Guimarães, Giovana Tardin Torrezan, Dirce Maria Carraro
Publikováno v:
Annals of surgical oncology. 28(7)
Phase III trials evaluating the role of secondary cytoreductive surgery (SCS) in recurrent ovarian cancer have pointed to the importance of patient selection. Two studies showed conflicting results regarding the benefit of SCS in BRCA1/2 mutation car
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81e6fda1b708b1e8838203456ea52490
https://pubmed.ncbi.nlm.nih.gov/33221980
https://pubmed.ncbi.nlm.nih.gov/33221980
Autor:
Adriana Regina Gonçalves Ribeiro, Alexandre Andre Balieiro Anastacio da Costa, Rafaela Pirolli, Viviane Teixeira Loiola de Alencar, Mariana Romero de Oliveira, Glauco Baiocchi, Andrea Paiva Gadelha Guimarães, Felipe Leonardo Estati
Publikováno v:
Web of Science
e18059 Background: The benefit of dose dense chemotherapy (ddCT) in the adjuvant treatment of ovarian carcinoma (OC) is not clear. There is one positive Japanese trial and two negative trials in non-Asian patients, which differed from the JGOG 3016 t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2ee2bbbd5b1ddd7e49ad006cb6feb12
https://doi.org/10.1200/jco.2020.38.15_suppl.e18059
https://doi.org/10.1200/jco.2020.38.15_suppl.e18059
Autor:
Felipe Leonardo Estati, Adriana Regina Gonçalves Ribeiro, Viviane Teixeira Loiola de Alencar, Giovana Tardin Torrezan, Maria Nirvana Formiga, Alexandre Andre Balieiro Anastacio da Costa, Dirce Maria Carraro, Rafaela Pirolli, Glauco Baiocchi, Andrea Paiva Gadelha Guimarães
Publikováno v:
Web of Science
6076 Background: Germline BRCA pathogenic variants are present in 15% to 25% of ovarian carcinoma patients. These tumors are more sensitive to platinum and PARP inhibitor therapy and have a better prognosis. Two retrospective studies with limited num
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c70f4a8f7e24915dc87656e508b4947
https://doi.org/10.1200/jco.2020.38.15_suppl.6076
https://doi.org/10.1200/jco.2020.38.15_suppl.6076
Autor:
Viviane Teixeira Loiola de Alencar, Adriana Regina Gonçalves Ribeiro, Alexandre Andre Balieiro Anastacio da Costa, Glauco Baiocchi, Andrea Paiva Gadelha Guimarães, Rafaela Pirolli, Felipe Leonardo Estati
Publikováno v:
Web of Science
e18043 Background: Neoadjuvant chemotherapy (NACT), followed by interval debulking surgery (IDS), is a possible approach to patients with stages IIIC and IV epithelial ovarian cancer who are most likely to have suboptimal results with upfront surgery
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90b34e48eed3aaaec66ebcb604f92ffe
https://publons.com/wos-op/publon/48894993/
https://publons.com/wos-op/publon/48894993/
